Stock Update (NASDAQ:AVNR): Football Hall-of-Famer Barry Sanders Tackles Pseudobulbar Affect
New research shows 99 percent of former professional football players surveyed by the Gridiron Greats Assistance Fund, Inc., have suffered a head injury, repeated concussions, or a blow to the head sometime during their football career. More concerning is that a third of these players admit to experiencing symptoms consistent with a little-known neurological condition caused by brain injury called Pseudobulbar Affect (PBA); and most were unaware that PBA symptoms may result from head… Read more »
Shares of Avanir Pharmaceuticals Inc closed last Monday at $16.96 . AVNR has a 1-year high of $17.05 and a 1-year low of $3.02. The stock’s 50-day moving average is $16.94 and it’s 200-day moving average is $10.90.
On the ratings front, Avanir Pharmaceuticals Inc has been the subject of a number of recent research reports. In a report published on December 15, analyst Ritu Baral from Cowen downgraded AVNR to Hold, with a price target of $17, which represents a slight upside potential from current levels. Separately, on December 3, Deutsche Bank`s Alethia Young downgraded Avanir Pharmaceuticals Inc shares to Hold .
In total, 4 research analysts have assigned a Hold rating and one research analyst has given a a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $16.96 which is 2.2% above where the stock closed last Monday.
Avanir Pharmaceuticals is a biopharmaceutical company engaged in acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders.